One to Watch and Two to Avoid: Trustmark, Tandem Diabetes Care, and Apogee

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. These companies carry less risk than penny stocks but are not immune to volatility as they lack the scale advantages of their larger peers. This can cause headaches for even the most seasoned professionals, which is why we started StockStory - to help you separate the good companies from the bad.

Here is one stock under $50 with massive upside potential and two that could be down big.

Two Stocks Under $50 to Sell:

Apogee (APOG)

Share Price: $38

Apogee (NASDAQ:APOG) sells architectural products and services such as high-performance glass for commercial buildings. However, the company's sales have stagnated over the last five years, and projected sales for the next 12 months are flat. Additionally, capital intensity has ramped up over the last five years as its free cash flow margin decreased by 2.8 percentage points. At $38 per share, Apogee trades at 9x forward P/E. To fully understand why you should be careful with APOG, check out our full research report (it’s free).

Tandem Diabetes (TNDM)

Share Price: $20.55

Tandem Diabetes Care (NASDAQ:TNDM) develops and manufactures automated insulin delivery systems that help people with diabetes manage their blood glucose levels. However, disappointing pump shipments over the past two years suggest it might have to lower prices to accelerate growth. Additionally, earnings per share fell by 42.6% annually over the last five years while its revenue grew, showing its incremental sales were much less profitable. Limited cash reserves may force the company to seek unfavorable financing terms that could dilute shareholders. Tandem Diabetes’s stock price of $20.55 implies a valuation ratio of 34.6x forward EV-to-EBITDA. Read our free research report to see why you should think twice about including TNDM in your portfolio, it’s free.

One Stock Under $50 to Watch:

Trustmark (TRMK)

Share Price: $34.08

Tracing its roots back to 1889 in Mississippi, Trustmark (NASDAQ:TRMK) is a financial services organization providing banking, wealth management, insurance, and mortgage services across five southeastern states. The company has decent 9.2% annual net interest income growth over the last four years, beating most of its peers. Additionally, earnings growth has massively outpaced its peers over the last two years as its EPS has compounded at 9.5% annually. Balance sheet strength has increased this cycle as its 20.2% annual tangible book value per share growth over the last two years was exceptional. Trustmark is trading at $34.08 per share, or 1x forward P/B. Is now a good time to buy? See for yourself in our in-depth research report, it’s free.

High-Quality Stocks for All Market Conditions

Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today for free.